Provided by Tiger Trade Technology Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc.

0.2780
-0.0433-13.48%
Post-market: 0.28950.0115+4.14%16:59 EST
Volume:14.55M
Turnover:4.16M
Market Cap:31.69M
PE:-0.64
High:0.3100
Open:0.2910
Low:0.2500
Close:0.3213
52wk High:2.17
52wk Low:0.2500
Shares:114.00M
Float Shares:111.00M
Volume Ratio:1.82
T/O Rate:13.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4340
EPS(LYR):-0.9026
ROE:-916.17%
ROA:-130.48%
PB:6.97
PE(LYR):-0.31

Loading ...

Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 23

BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million

Reuters
·
Dec 23

Reviva Pharmaceuticals: Negative Symptoms/Bipolar Trial Is Projected to Cost About $30 Mln

THOMSON REUTERS
·
Dec 23

Reviva Pharmaceuticals Plans RECOVER-2 Phase 3 Trial for Schizophrenia Drug Brilaroxazine

Reuters
·
Dec 23

Reviva Pharmaceuticals Holdings Inc - Recover-2 Trial Planned for H1 2026

THOMSON REUTERS
·
Dec 23

Reviva Pharmaceuticals Holdings Inc - FDA Recommends Second Phase 3 Trial for Brilaroxazine

THOMSON REUTERS
·
Dec 23

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

THOMSON REUTERS
·
Dec 23

Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 19

Alliance Global Partners Sticks to Their Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)

TIPRANKS
·
Nov 18

Reviva Pharmaceuticals Q3 net loss narrows

Reuters
·
Nov 14

BRIEF-Reviva Pharmaceuticals Q3 EPS USD -0.06

Reuters
·
Nov 14

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire
·
Nov 14

Reviva Pharmaceuticals Holdings options imply 21.1% move in share price post-earnings

TIPRANKS
·
Nov 14

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025

GlobeNewswire
·
Nov 12

H.C. Wainwright Sticks to Their Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)

TIPRANKS
·
Nov 11

Reviva Pharmaceuticals Granted European Patent for Brilaroxazine in Pulmonary Fibrosis Treatment

Reuters
·
Nov 10

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis

THOMSON REUTERS
·
Nov 10

Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference

GlobeNewswire
·
Oct 29

Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 29

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

GlobeNewswire
·
Oct 28